Marengo Therapeutics Expands Executive Leadership Team with Svetlana Makhni Joining as Chief Financial Officer

CAMBRIDGE, Mass., June 15, 2022 /PRNewswire/ — Marengo Therapeutics, Inc., a organization groundbreaking novel therapeutics that directly goal the Vβ chain of the T cell receptor (TCR) to activate the correct T mobile subsets to fight cancer, today introduced the appointment of Svetlana Makhni as Chief Economical Officer, more bolstering Marengo’s C-suite leadership qualifications.

“Svetlana delivers sturdy leadership expertise in the biopharmaceutical marketplace and deep money acumen to our management crew,” said Zhen Su, M.D., MBA, Chief Govt Officer of Marengo. “Svetlana will participate in an critical job in our journey to advance our first-in-course STAR therapeutic system into the clinic and bring progressive treatments to most cancers sufferers in have to have.”

Ms. Makhni is a seasoned biotech professional with about 15 yrs of knowledge in finance, business enterprise improvement and operations. She earlier served as Chief Monetary Officer at Escient Prescription drugs, a medical-stage biotech firm, and ahead of that, she was Main Economical Officer and Head of Functions at Bierman ABA, a major national, multi-internet site supplier of behavioral overall health providers. Prior to becoming a member of Bierman, she worked for nearly a decade in health care financial commitment banking at numerous major economical establishments which include BMO Funds Markets, Goldman Sachs, Westbrook Partners and the Blackstone Group. Ms. Makhni acquired her B.S. in Finance and Accounting from The Wharton Faculty and her MBA from Harvard Company College.

“Marengo’s mission to promote lifelong security in opposition to cancer is actually inspirational and aligns with my enthusiasm to convey everyday living-shifting therapies to individuals with large unmet requirements,” said Ms. Makhni. “I am keen to work with this devoted team of gurus and visionaries to development the firm’s lead candidate to the clinic and strengthen the lives of sufferers.”

Constructing on the new senior appointments of Ke Liu, M.D., Ph.D., as Chief Growth Officer and Bruce Chabner, M.D., as Senior Strategic Advisor, Ms. Makhni rounds out Marengo’s seasoned govt management group, comprised of Zhen Su, M.D., MBA, Main Govt Officer Andrew Bayliffe, Ph.D., Main Scientific Officer and Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., Main Medical Officer.

About Marengo Therapeutics
Marengo Therapeutics, Inc, an ATP firm, is groundbreaking very first-in-course therapeutics that activate the ideal immune reaction to promote lifelong security towards most cancers. With a passionate team of focused experts professional in immunology and oncology, Marengo’s proprietary Selective T Mobile Activation Repertoire (STAR) system leverages an in depth biological understanding of T mobile purpose and receptor signaling to generate a world in which everyone’s immune system can defeat cancer. To learn much more, go to www.marengotx.com.

View authentic content material to download multimedia:https://www.prnewswire.com/information-releases/marengo-therapeutics-expands-executive-leadership-team-with-svetlana-makhni-becoming a member of-as-main-money-officer-301567912.html

Supply Marengo Therapeutics